Merck relaunches customer collaboration centers with new concept and M Lab name
Merck's M Lab Collaboration Centers offer customers the opportunity to explore, learn and collaborate at the company's global network of sites around the world, solving the challenges they face every day.
Enables explorations of new technologies and solutions to address development and manufacturing challenges.
Merck is relaunching its global network of customer collaboration centers, providing customers a shared, exploratory environment with scientists and engineers working to solve their toughest biomanufacturing challenges, helping accelerate development of new therapies.
Formerly known as biomanufacturing science training centers, the new state-of-the-art M Lab concept will include a simulated manufacturing environment that provides customers a setting that fosters education and full end-to-end development support. The centers are created especially for customer collaboration in which problem solving for processing issues take place. Customers participate in product demonstrations, hands-on training and experiments, as well as apply best practices and new approaches to develop, optimize and scale-up processes and simplify global technology transfer.
"We are the only company that offers full end-to-end process training, and we do it side-by-side with our customers, working together to solve critical challenges," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science.
Now reimagined and reengineered as M Lab Collaboration Centers, Merck has taken its industry-leading concept to the next level by creating unique and inspiring settings where customers can explore new ways to increase productivity and improve processes in close collaboration Merck's team of experts.
"These centers have been an important resource for our customers and the biopharma industry for more than two decades and will continue to be important as we grow," Batra added.
Merck unveiled its first remodeled center in Tokyo, Japan on 29 June 2016. The network, established in 1995, will also include locations in Brazil, China, France, India, Singapore, South Korea and the United States. Formal relaunch of these centers will take place throughout the remainder of 2016 and 2017 with openings of the new M Lab concept in France, India, China, South Korea and the US.
Each center will welcome customers, collaborators from government, academia, regulatory bodies and industry associations, offering application best practices and knowledge sharing tailored to address the specific needs of the local biomanufacturing industry. Customers will have access to sizing and simulation tools and methodologies as well as analytical and modeling support. Hands-on and classroom-style training sessions and education programs are also provided.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...